Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PHATHOM PHARMACEUTICALS, INC. reported revenue of $175M, up 216.9% year over year. Operating margin was -91.4% and net margin -126.3%, on a free-cash-flow margin of -95.4% with capital expenditure at 0.1% of revenue. Every figure is computed directly from PHAT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $175M | -91.4% | -126.3% |
| FY2024 | $55M | -502.2% | -605.1% |
| FY2023 | $1M | -24532.6% | -29558.9% |
| FY2022 | $0M | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does PHAT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.